Novel Anti-obesity Drugs and Plasma Lipids

Anti-obesity medication or weight loss drugs are all pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise. Lorcaserin (Belviq) was approved for obesity with other co-morbidities. The average weight loss by study participants was modest, but the most common side effects of the drug are considered benign. Some anti-obesity drugs can have severe, even, lethal side effects, fen-phen being a famous example

Fen-phen was reported through the FDA to cause abnormal echocardiograms, heart valve problems, and rare valvular diseases. One of, if not the first, to sound alarms was Sir Arthur MacNalty, Chief Medical Officer (United Kingdom). As early as the 1930s, he warned against the use of Dinitrophenol as an anti-obesity medication and the injudicious and/or medically unsupervised use of thyroid hormone to achieve weight reduction. The side effects are often associated with the medication's mechanism of action. In general, stimulants carry a risk of high blood pressure, fasterheart rate, palpitations, closed-angle glaucoma, drug addiction, restlessness, agitation, and insomnia.

  • Appetite suppression-Catecholamines and their derivatives
  • Lipid Metabolic Enzymes for Obesity Treatment
  • Obesity and Pharmacokinetics
  • Target G Protein-Coupled Receptors (Gpcrs)-Regulating Drugs
  • Methionine Aminopeptidase 2 (MetAP2) Inhibitors
  • Bile Acid Brake for Therapeutic drugs of Diabesity
  • Vagal Blocking Therapy for Obesity
  • Dexfenfluramine for Obesity Treatment

Related Conference of Novel Anti-obesity Drugs and Plasma Lipids

Novel Anti-obesity Drugs and Plasma Lipids Conference Speakers